Premium
Nasopharyngeal carcinoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations
Author(s) -
BenAmi Tal,
Kontny Udo,
Surun Aurore,
Brecht Ines B.,
Almaraz Ricardo López,
Dragomir Monica,
Pourtsidis Apostolos,
Casanova Michela,
Fresneau Brice,
Bisogno Gianni,
Schneider Dominik T.,
Reguerre Yves,
Bien Ewa,
StachowiczStencel Teresa,
Österlundh Gustaf,
Wygoda Marc,
Janssens Geert O,
Zsiros József,
Jehanno Nina,
Brisse Herve J,
Gandola Lorenza,
Christiansen Hans,
Claude Line,
Ferrari Andrea,
RodriguezGalindo Carlos,
Orbach Daniel
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.29018
Subject(s) - medicine , nasopharyngeal carcinoma , guideline , concomitant , induction chemotherapy , radiation therapy , chemotherapy , chemoradiotherapy , oncology , disease , intensive care medicine , pediatrics , pathology
Nasopharyngeal carcinoma (NPC) is a rare pediatric tumor. Collaborative studies performed over the last decades showed improved results compared to historical data, but standardized guidelines for diagnosis and management of pediatric NPC are still unavailable. This study presents a European consensus guideline for the diagnosis and treatment of pediatric NPC developed by the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Main recommendations include induction chemotherapy with cisplatin and 5‐flurouracil, concomitant chemoradiotherapy in advanced disease, and to consider maintenance treatment with interferon beta (IFN‐β) for selected high‐risk patients. Dose adjustments of radiotherapy based on response to induction chemotherapy may decrease the rates of long‐term treatment‐related complications that affect most of the survivors.